艾滋病人抗病毒治疗过程中ALT、LDH、AST、m-AST、TBIL、DBIL等生化指标研究
|
摘要
目的研究艾滋病人抗病毒治疗过程中ALT、LDH、AST、m-AST、TBIL、DBIL等生化指标。方法选取我市定点医院2016年1月至2018年1月收治的100例艾滋病患者资料为研究对象,通过艾滋病疫情系统数据下载,进行回顾性分析,根据治疗方案中是否存在奈韦拉平(NVP)为标准,研究艾滋病人抗病毒治疗过程中ALT、LDH、AST、m-AST、TBIL、DBIL等生化指标检测结果。结果 NPV组T BIL、DBIL水平相较于非NPV组无明显差异,P>0.05,无统计学意义。非NVP组ALT、LDH、AST、m-AST水平相较于NPV组有明显升高的趋势,P<0.05,有统计学意义;N VP组中血清转氨酶升高1例、黄疸2例、皮疹2例,不良反应率为10.0%;非N VP组中血清转氨酶升高2例、黄疸2例、皮疹3例,不良反应率为14.0%;组间计算χ2值为6.254,P值为0.009,非NVP组显著高于NVP组,P<0.05,差异有统计学意义。结论 N VP相较于EF V疗效无明显差异,但存在一定的肝脏毒性,加强对ALT、LDH、AST、m-AST、TBIL、DBIL指标的检测观察,能够准确判断用药时机,值得推广。
Objective To study the biochemical indicators of ALT,LDH,AST,m-AST,TBIL,DBIL in AIDS patients during antiviral treatment.Methods The data of 100 cases of AIDS patients admitted in our city designated hospital from January to 2016 January 2018 were selected as the research object.Through the data downloading of the AIDS epidemic system,a retrospective analysis was carried out.According to the existence of NVP as the standard,ALT,LDH,AST,m-AST in the process of AIDS treatment were studied.The results of biochemical indexes such as TBIL and DBIL were detected.Results TBIL and DBIL levels in group NPV were not significantly different from those in non NPV group,P>0.05,with no statistically significant.The levels of ALT,LDH,AST and m-AST in non NVP group were significantly higher than those in NPV group,P<0.05,with statistically significant.In group NVP,serum transaminase was elevated in 1 cases,jaundice in 2 cases,and rash in 2 cases,with an adverse reaction rate of 10.0%.There were2 cases of serum transaminase elevation in non NVP group,2 cases of jaundice and 3 cases of rash.The rate of adverse reaction was14.0%,χ2=6.254,P=0.009 in the group.The non NVP group was significantly higher than the group NVP,P<0.05,the difference was statistically significant.Conclusion There is no significant difference in the effect of NVP compared with EFV,but there is a certain liver toxicity.It is necessary to strengthen the detection and observation of ALT,LDH,AST,m-AST,TBIL,DBIL,and can accurately judge the time of drug use,it is worth promoting.
Objective To study the biochemical indicators of ALT,LDH,AST,m-AST,TBIL,DBIL in AIDS patients during antiviral treatment.Methods The data of 100 cases of AIDS patients admitted in our city designated hospital from January to 2016 January 2018 were selected as the research object.Through the data downloading of the AIDS epidemic system,a retrospective analysis was carried out.According to the existence of NVP as the standard,ALT,LDH,AST,m-AST in the process of AIDS treatment were studied.The results of biochemical indexes such as TBIL and DBIL were detected.Results TBIL and DBIL levels in group NPV were not significantly different from those in non NPV group,P>0.05,with no statistically significant.The levels of ALT,LDH,AST and m-AST in non NVP group were significantly higher than those in NPV group,P<0.05,with statistically significant.In group NVP,serum transaminase was elevated in 1 cases,jaundice in 2 cases,and rash in 2 cases,with an adverse reaction rate of 10.0%.There were2 cases of serum transaminase elevation in non NVP group,2 cases of jaundice and 3 cases of rash.The rate of adverse reaction was14.0%,χ2=6.254,P=0.009 in the group.The non NVP group was significantly higher than the group NVP,P<0.05,the difference was statistically significant.Conclusion There is no significant difference in the effect of NVP compared with EFV,but there is a certain liver toxicity.It is necessary to strengthen the detection and observation of ALT,LDH,AST,m-AST,TBIL,DBIL,and can accurately judge the time of drug use,it is worth promoting.
引文
[1]潘婵.输血对患者ALT、LDH、AST、m-AST、TBIL、DBIL等生化指标的影响分析[J].医药前沿,2016,6(18):155-156.
[2]朱荣华,杨雪梅.艾滋病人抗病毒治疗过程中ALT、TBIL生化指标分析[J].医药前沿,2011,1(8):47-48.
[3]陈莉贞,杜勤.HIV感染者早期抗病毒治疗CD4+T淋巴细胞动态趋势观察[C]//全国寄生虫病高峰论坛暨2016年浙江省热带病与寄生虫病学术年会论文汇编,2016.
[4]陈莉贞,胡驾云,姚鹏,等.艾滋病患者抗病毒治疗后CD4+T淋巴细胞的复常情况和不良反应[J].国际流行病学传染病学杂志,2016,43(5):313-317.
[5]杜巍,刘铮,李兴库.艾滋病抗病毒治疗疗效检验指标的研究及应用分析[J].中国现代药物应用,2017,11(10):79-80.
[6]余华凤.艾滋病免费抗病毒治疗的临床观察[J].心理医生,2017,23(2):166-167.
[7]曾亮,马烨.不同死亡评价指标在艾滋病防治中的应用[J].中华流行病学杂志,2016,37(5):745-748.
[8]向信春,丁芳,李佳豫.8例艾滋病患者进行依非韦伦、拉米夫定和替诺福韦治疗的生化指标分析[J].中国医药指南,2015,13(12):157-158.
[9]李繁,廖存章,李远,等.艾滋病抗病毒治疗疗效检验指标的研究及应用[J].河北医学,2013,19(9):1371-1374.
[10]梁林慧,黄承乐.获得性免疫缺陷综合征抗病毒治疗对生化计量指标的影响[J].医学综述,2017,23(16):3211-3215.
[11]万薇.艾滋病患者抗病毒治疗疗效分析[J].医药前沿,2014,4(33):392-393.
[12]白一春,李骁,夏仁兴.司他夫定联合拉米夫定与奈韦拉平抗病毒方案治疗对艾滋病患者免疫功能的影响及其安全性分析[J].临床和实验医学杂志,2018,17(1):63-67.
[13]文湖钧,徐鹏,吕繁,等.我国部分地区艾滋病抗病毒治疗服务体系现状及特点分析[J].实用预防医学,2018,25(3):378-380.
[14]艾莉莎,孙昳,郭殊君.艾滋病抗病毒治疗后皮疹应用中西医结合治疗的效果[J].包头医学院学报,2018,35(2).64-548.
[15]刘笑宇,李铭,李莉,等.艾滋病抗病毒治疗新药的研究进展[J].人人健康,2018,27(2).54-55.
[2]朱荣华,杨雪梅.艾滋病人抗病毒治疗过程中ALT、TBIL生化指标分析[J].医药前沿,2011,1(8):47-48.
[3]陈莉贞,杜勤.HIV感染者早期抗病毒治疗CD4+T淋巴细胞动态趋势观察[C]//全国寄生虫病高峰论坛暨2016年浙江省热带病与寄生虫病学术年会论文汇编,2016.
[4]陈莉贞,胡驾云,姚鹏,等.艾滋病患者抗病毒治疗后CD4+T淋巴细胞的复常情况和不良反应[J].国际流行病学传染病学杂志,2016,43(5):313-317.
[5]杜巍,刘铮,李兴库.艾滋病抗病毒治疗疗效检验指标的研究及应用分析[J].中国现代药物应用,2017,11(10):79-80.
[6]余华凤.艾滋病免费抗病毒治疗的临床观察[J].心理医生,2017,23(2):166-167.
[7]曾亮,马烨.不同死亡评价指标在艾滋病防治中的应用[J].中华流行病学杂志,2016,37(5):745-748.
[8]向信春,丁芳,李佳豫.8例艾滋病患者进行依非韦伦、拉米夫定和替诺福韦治疗的生化指标分析[J].中国医药指南,2015,13(12):157-158.
[9]李繁,廖存章,李远,等.艾滋病抗病毒治疗疗效检验指标的研究及应用[J].河北医学,2013,19(9):1371-1374.
[10]梁林慧,黄承乐.获得性免疫缺陷综合征抗病毒治疗对生化计量指标的影响[J].医学综述,2017,23(16):3211-3215.
[11]万薇.艾滋病患者抗病毒治疗疗效分析[J].医药前沿,2014,4(33):392-393.
[12]白一春,李骁,夏仁兴.司他夫定联合拉米夫定与奈韦拉平抗病毒方案治疗对艾滋病患者免疫功能的影响及其安全性分析[J].临床和实验医学杂志,2018,17(1):63-67.
[13]文湖钧,徐鹏,吕繁,等.我国部分地区艾滋病抗病毒治疗服务体系现状及特点分析[J].实用预防医学,2018,25(3):378-380.
[14]艾莉莎,孙昳,郭殊君.艾滋病抗病毒治疗后皮疹应用中西医结合治疗的效果[J].包头医学院学报,2018,35(2).64-548.
[15]刘笑宇,李铭,李莉,等.艾滋病抗病毒治疗新药的研究进展[J].人人健康,2018,27(2).54-55.